Leveraging Trace Element Chips to Transform Global Animal Nutrition Interview with Li Dejun, Vice President of Sichuan Jilongda Biotechnology Group Co., Ltd. In the grand development history of the feed industry in China, trace elements, though small in proportion, are akin to “chips” in the information industry, determining the efficiency and safety of the entire … Read more
Name: Ying’en Biotech-B Code: 09606.HK Current Stock Price: HKD 331.2 (as of the close on 2025/11/13) Market Capitalization: HKD 29.243 billion Industry: Biotechnology (ADC Drug Development) As a significant player in the global antibody-drug conjugate (ADC) field, Ying’en Biotech has rapidly advanced its core products and international collaboration strategies, achieving a year-on-year revenue growth of … Read more
1. OpenAI Releases Next-Generation Multimodal Model GPT-4o, Real-time Interaction Capabilities Shake the Industry OpenAI has launched the next-generation artificial intelligence model GPT-4o (with “o” representing omni, meaning all-encompassing), which achieves a core breakthrough in seamless real-time interaction across text, speech, and vision. This model’s response speed closely matches human conversational pace and can analyze environmental … Read more
Recently, the U.S. restrictions on the Chinese biotechnology sector have shifted from “expectation” to “actual action”. On September 12, 2025, the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) placed 23 Chinese entities on the “Entity List”, including three biotechnology companies: Beijing Tianyi Huiyuan Biotechnology Co., Ltd., Beijing Qinke Biotechnology Co., Ltd., and … Read more
In-Depth Analysis of the Competitive Landscape in the ADC Drug Industry: Moats, Growth Drivers, and Risk Perspectives Core Summary The Chinese antibody-drug conjugate (ADC) industry is transitioning from a rapid expansion phase to an “innovation integration” phase. This transformation is driven by three core factors: stricter regulations (enhanced NMPA standards and NRDL price negotiations), technological … Read more
Antibody-drug conjugates (ADCs) are a class of biotherapeutic drugs targeting cancer, combining the targeting capability of monoclonal antibodies (mAbs) with the anticancer efficacy of cytotoxic drugs (Payload). The antibody and payload are linked by a linker, allowing specific drugs to be delivered to cancer cells targeted by the antibody. Once inside the cell, the linked … Read more
Recently, the ADC (Antibody-Drug Conjugate) conference has been held one after another, with major biotech companies competing to report their ADC pipelines. It is expected that 2024 will still be the main stage for ADCs. Developing an entry-level ADC seems not too difficult, but how to evaluate the pharmacology and toxicology in the preclinical stage … Read more
Little Orange Lantern Network WeChat ID:ivdnet Leading brand in in vitro diagnostics media (www.iivd.net) In recent years, with the continuous development of precision medicine, mass spectrometry technology, as a high-tech platform for precision diagnosis and treatment, has been increasingly applied in clinical settings. Although China started late compared to foreign countries, especially North America, the … Read more
Since the concept of ADC was proposed in 1900, it has existed as a new type of cancer treatment method. Although its development has faced many challenges over the past century, top scientists in the relevant fields around the world have been conducting years of experiments and iterations to improve safety, reduce off-target effects, and … Read more
-Introduction– $43 billion shock and $8.4 billion inquiry In March 2023, a thunderous announcement shook the global pharmaceutical industry. Pfizer, a giant in the COVID-19 vaccine sector, declared it would acquire Seagen, the “pioneer” of antibody-drug conjugates (ADC), for a staggering $43 billion. This is not only the largest merger in the pharmaceutical sector since … Read more